Literature DB >> 7642872

Salutary effect of disopyramide on left ventricular diastolic function in hypertrophic obstructive cardiomyopathy.

H Matsubara1, S Nakatani, S Nagata, F Ishikura, Y Katagiri, T Ohe, K Miyatake.   

Abstract

OBJECTIVES: The purpose of this study was to estimate the effect of disopyramide on left ventricular diastolic function in patients with hypertrophic obstructive cardiomyopathy.
BACKGROUND: Although disopyramide has been reported to lessen clinical symptoms in patients with hypertrophic obstructive cardiomyopathy, few data exist regarding its effect on diastolic function in these patients.
METHODS: Thirteen patients with hypertrophic cardiomyopathy (six with and seven without left ventricular outflow obstruction) were examined. Before and after intravenous disopyramide, hemodynamic and angiographic studies were performed.
RESULTS: In patients with outflow obstruction, pressure gradient at the outflow tract decreased from a mean +/- SD of 100 +/- 45 to 26 +/- 33 mm Hg (p < 0.01). Although systolic function was similarly impaired in both groups, the time constant of left ventricular pressure decay (tau) shortened from 56 +/- 10 to 44 +/- 8 ms (p < 0.01) and the constant of left ventricular chamber stiffness (kc) decreased from 0.049 +/- 0.017 to 0.038 +/- 0.014 m2/ml (p < 0.01) only in patients with outflow obstruction. Shortening in tau correlated best with decrease in left ventricular systolic pressure (r = 0.84, p < 0.01). In contrast, tau was prolonged from 52 +/- 10 to 64 +/- 11 ms (p < 0.01) and kc was unchanged in patients without outflow obstruction.
CONCLUSIONS: The primary effects of disopyramide on the hypertrophied left ventricle were negative inotropic and negative lusitropic. However, left ventricular diastolic properties in patients with outflow obstruction were improved with a decrease in outflow pressure gradient. Relief of clinical symptoms in hypertrophic obstructive cardiomyopathy with disopyramide might be due in part to improvement of diastolic function, which appears secondary to the reduction in ventricular afterload.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642872     DOI: 10.1016/0735-1097(95)00229-W

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Recent advances in diagnosis and management of hypertrophic cardiomyopathy.

Authors:  B B Siswanto; R Aryani
Journal:  Heart Asia       Date:  2009-01-01

2.  Disopyramide improves the balance between myocardial oxygen supply and demand in patients with hypertrophic obstructive cardiomyopathy.

Authors:  K Niki; M Sugawara; R Asano; T Oka; Y Kondoh; S Tanino; K Iwade; N Magosaki; H Kasanuki; S Hosoda
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 3.  Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.

Authors:  Chiara Palandri; Lorenzo Santini; Alessia Argirò; Francesca Margara; Ruben Doste; Alfonso Bueno-Orovio; Iacopo Olivotto; Raffaele Coppini
Journal:  Drugs       Date:  2022-06-13       Impact factor: 11.431

4.  Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies.

Authors:  Ingegerd Östman-Smith
Journal:  Rev Recent Clin Trials       Date:  2014

Review 5.  Hypertrophic cardiomyopathy: a review.

Authors:  Brian A Houston; Gerin R Stevens
Journal:  Clin Med Insights Cardiol       Date:  2015-01-26

6.  Hypertrophic Cardiomyopathy in a Young Adult with RV Aneurysm: Report of a Rare Finding and Review of the Literature.

Authors:  Ahmed M Abdel-Razek; Leonard Y Lee; Robert Tozzi
Journal:  Heart Views       Date:  2011-07

Review 7.  Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice.

Authors:  Mark V Sherrid
Journal:  Curr Cardiol Rev       Date:  2016
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.